share_log

Maia Biotechnology Receives FDA Orphan Drug Designation For THIO For The Treatment Of Small-Cell Lung Cancer

Maia Biotechnology Receives FDA Orphan Drug Designation For THIO For The Treatment Of Small-Cell Lung Cancer

Maia Biotechnology 因用于治疗小细胞肺癌的 THIO 获得美国食品药品管理局孤儿药认证
Benzinga Real-time News ·  2022/08/02 08:05

$MAIA Biotechnology(MAIA.US)$ ("MAIA", the "Company"), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to THIO, a telomere-targeting agent currently in development to evaluate its activity in multiple cancer indications, for the treatment of small-cell lung cancer (SCLC). 

$MAIA 生物技术 (MAIA.US) $ （“MAIA”，“公司”）是一家专注于开发潜在的同类首创肿瘤药物的靶向疗法、免疫肿瘤学公司，今天宣布，美国食品药品监督管理局（FDA）已授予用于治疗小细胞肺癌（SCLC）的端粒靶向药物THIO（ODD）的孤儿药称号（ODD）。

This is the second orphan drug designation granted to THIO, following receipt of orphan designation for hepatocellular carcinoma (HCC).

这是继获得肝细胞癌（HCC）孤儿称号后，THIO获得的第二个孤儿药称号。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发